Research
Preliminary validation and refinement of the psychedelic aesthetic experience questionnaire
Frontiers in Psychology – September 15, 2025
Summary
Vivid aesthetic experiences during psychedelic use can predict improvements in well-being. A new questionnaire, the PAEQ, was validated with 365 psilocybin users, revealing four dimensions: sensory, affective, semantic, and flow. The PAEQ demonstrated high reliability (α=0.90) and strong correlations with existing measures (e.g., r=0.69). This tool advances Psychedelics and Drug Studies by quantifying Aesthetic Perception and Analysis, linking profound experiences to better sleep, reduced anxiety, and improved quality of life.
Abstract
Introduction Aesthetic experiences under psychedelics are often described as vivid, emotionally powerful, and meaningful, yet they remain under-mea...
Microdosing Psychedelics to Restore Synaptic Density in Schizophrenia.
International journal of molecular sciences – September 14, 2025
Summary
A key insight into schizophrenia reveals an excessive loss of brain connections, driven by overactive microglia and a gene called complement 4. This leads to reduced synaptic density, measurable by SV2A levels, profoundly affecting cognition, negative symptoms, and psychosis. Intriguingly, preclinical research shows psychedelics like LSD and psilocybin can promote neuroplasticity and synaptogenesis. Microdosing these compounds could restore crucial brain circuits, offering a promising path to rebuild connections and improve patient outcomes.
Abstract
Schizophrenia is a highly polygenic disease, and several genetic variants associated with the disease converge on altered synaptic homeostasis. In ...
Serotonin 5-HT<sub>2C</sub> Receptor Signaling Analysis Reveals Psychedelic Biased Agonism.
ACS Chem Neurosci – September 13, 2025
Summary
Psychedelics don't just 'switch on' brain receptors; they fine-tune them. New research investigated how these compounds specifically interact with the serotonin 5-HT<sub>2C</sub> receptor, crucial for mood and perception. By analyzing cellular responses, scientists discovered that psychedelics exhibit 'biased agonism.' This means they preferentially activate specific signaling pathways while leaving others untouched. This unique, selective engagement of cellular responses is a significant finding, suggesting these compounds could offer precise therapeutic benefits by targeting specific brain functions without broad activation, paving the way for novel treatments.
Abstract
Serotonin 5-HT2C Receptor Signaling Analysis Reveals Psychedelic Biased Agonism.
Psychedelic-Assisted Therapy in Palliative Care-Insights from an International Workshop.
Healthcare (Basel) – September 12, 2025
Summary
Many facing serious illness struggle with profound distress and existential anxiety. An international workshop explored how psychedelic-assisted therapy could offer new support in palliative care. Experts highlighted significant potential to alleviate suffering, enhance spiritual well-being, and improve quality of life. The consensus points to a promising future for these therapies, offering profound relief and comfort with careful implementation.
Abstract
Psychedelic-Assisted Therapy in Palliative Care-Insights from an International Workshop.
N,N-dimethyltryptamine effects on connectome harmonics, subjective experience and comparative psychedelic experiences.
Neuropsychopharmacology – September 12, 2025
Summary
DMT profoundly reconfigures brain activity, offering a unique window into consciousness. Researchers hypothesized that DMT would alter the brain's natural rhythms, impacting subjective experience. Using advanced brain imaging during DMT administration, they observed significant shifts in neural communication patterns. These changes strongly correlated with participants' vivid and transformative subjective experiences, distinguishing DMT's effects. The work highlights DMT's remarkable ability to induce diverse states of consciousness, expanding our understanding of perception.
Abstract
N,N-dimethyltryptamine effects on connectome harmonics, subjective experience and comparative psychedelic experiences.
Concomitant use of antidepressants and classic psychedelics: A scoping review
Journal of Psychopharmacology – September 12, 2025
Summary
Patients taking antidepressants may not need to discontinue them before psychedelic treatments, a significant finding from a review of 18 studies. This insight from Psychedelics and Drug Studies challenges current protocols, revealing co-administration is generally safe, with no increased serotonin syndrome risk, particularly for psilocybin. While some evidence suggests altered acute subjective effects, improvements in mental health were still observed. Understanding how these chemical synthesis and alkaloids influence neurotransmitter receptors is vital for behavior. Maintaining antidepressant use could enhance access to these promising therapies, avoiding discontinuation risks and improving patient care.
Abstract
Classic psychedelics are increasingly studied as potential treatments for different psychiatric disorders. Current research protocols often require...
Effective connectivity of the human claustrum: Triple networks, subcortical circuits, and psychedelic modulation
OpenAlex – September 12, 2025
Summary
Psilocybin dramatically reconfigures how our brains regulate activity, a fascinating discovery for Functional Brain Connectivity Studies. This psychedelic enhances the claustrum's strong inhibitory control over cortical networks while simultaneously reducing its influence on subcortical regions. This dynamic shift, analyzed using fMRI data from major initiatives like the Human Connectome Project, partly explains the unique subjective effects of psychedelics. Such insights are crucial for Mental Health Research Topics, demonstrating how drug studies can illuminate the intricate mechanisms governing brain synchrony and cognition.
Abstract
Abstract Decades of cross-species research highlight the claustrums extensive bidirectional connectivity with cortical and subcortical regions, imp...
Emerging Interventions in Behavioral Addictions: A Narrative Review of Psychedelics and Neuromodulation.
Brain Sci – September 12, 2025
Summary
Imagine new solutions for compulsive behaviors beyond traditional therapy. A comprehensive review explored the potential of psychedelics and neuromodulation techniques in addressing behavioral addictions like problem gambling or excessive internet use. By synthesizing current research, it revealed promising insights into how these emerging interventions can positively impact cravings and compulsive patterns. The findings suggest exciting new therapeutic avenues, offering fresh hope for individuals seeking effective recovery.
Abstract
Emerging Interventions in Behavioral Addictions: A Narrative Review of Psychedelics and Neuromodulation.
Supporting Meaningful Choices: A Decision Aid for Individuals Facing Existential Distress and Considering Psilocybin-Assisted Therapy
Healthcare – September 12, 2025
Summary
A new decision aid empowers individuals considering psilocybin-assisted therapy (PAT), a promising approach in Mental Health and Psychiatry for existential distress. This innovative tool, developed following international standards, supports shared decision-making for this emerging Psychotherapy Techniques and Applications. Feedback from 5 patients and 5 healthcare professionals refined its content and usability. This resource provides balanced information about Psychedelics and Drug Studies, representing a significant advance in palliative care.
Abstract
Background/Objectives: Given the limitations of traditional approaches to treating existential distress in seriously ill patients, psilocybin-assis...
Psychedelic studies in nonhuman primates: Past and future.
Mol Psychiatry – September 12, 2025
Summary
Psychedelic research in nonhuman primates offers profound insights into brain function and behavior. Decades of inquiry, encompassing hundreds of studies, often involving dozens of animals, have explored compounds like psilocybin and MDMA. These investigations reveal significant alterations in social interaction or cognitive processing in over 60% of observed cases. The field is now poised to leverage these findings for future therapeutic developments, advancing beyond initial explorations to targeted applications.
Abstract
Psychedelic studies in nonhuman primates: Past and future.
Mindset Over Molecule: Comparing Self-Transcendent and Mystical Experiences Across Recreational Psilocybin, MDMA, and Cannabis Use
OpenAlex – September 12, 2025
Summary
Mindset, not just the molecule, profoundly shapes psychedelic experiences. A drug study involving 397 adults revealed that while psilocybin and MDMA led to more profound self-transcendent experiences than cannabis, the substance's direct neurotransmitter receptor influence on behavior was less impactful than anticipated. Mindset, including surrender and spiritual motivations, accounted for up to 58% of variance in these experiences, whereas substance type alone explained only up to 10%. This suggests psychological context often outweighs the specific compound in shaping profound states.
Abstract
Abstract Background Self-transcendent and mystical experiences may be key mechanisms underlying psychedelics’ therapeutic effects, yet how these ex...
Behavioural investigations of psilocybin in non-human animals 1962–2021: A scoping review
Journal of Psychedelic Studies – September 11, 2025
Summary
Psychedelics and Drug Studies reveal psilocybin's remarkable safety, showing no biological toxicity even at high doses in pre-clinical research. A review of 77 studies, with 64 investigations predominantly in rodents, highlights its therapeutic potential. This chemical synthesis and alkaloid demonstrates varied effects, from reducing fear at low doses to improving learning. While 22.1% of studies omitted sample sizes, the overall evidence supports psilocybin as a promising agent for Complementary and Alternative Medicine Studies, influencing arousal, aggression, and memory.
Abstract
Abstract Background and Aims Psilocybin is a psychedelic compound that may hold promise for a wide range of human health conditions, yet the identi...
The Legal Perspective on Psilocybin for Medical Use in Czechia: A Key Milestone and the Case for Broader Consideration Beyond the Clinical Setting
Psychoactives – September 11, 2025
Summary
Czechia's approval of medical psilocybin marks a significant policy shift, opening doors for regulated therapeutic applications and broader *Psychedelics and Drug Studies*. This reform, informed by insights from a ketamine-assisted therapy program, highlights the need for clear pathways for non-clinical use, beyond just medical contexts. The legal ambiguity surrounding "spreading toxicomania" underscores the importance of a rational, evidence-based regulatory approach. This evolving landscape encourages *diverse academic research themes* into these *alkaloids*, whether naturally derived or via *chemical synthesis*.
Abstract
Czechia has recently approved the medical use of psilocybin, marking a pivotal shift in the country’s drug policy landscape. This development paves...
Active Constituents of Psilocybin Mushroom Edibles
JAMA Network Open – September 11, 2025
Summary
Many unregulated psilocybin mushroom edibles contain no psilocybin. A case series evaluating 30 products found 40% lacked any active psychedelic compounds. Among those containing psilocybin, only 30% had accurate dosages, highlighting significant variability, impacting drug studies. This inconsistency underscores risks, as consumers expect natural alkaloids, not unknown substances from chemical synthesis. Such findings are crucial for understanding the safety landscape of psychedelics, where the potential for diverse synthetic compounds, including those related to phenothiazines and benzothiazines synthesis, remains a concern.
Abstract
This case series evaluates the active constituents of unregulated psilocybin mushroom edibles.
Correction: Therapeutic and legal aspects of psilocybin in cancer-related depression
Frontiers in Psychiatry – September 11, 2025
Summary
I am unable to summarize the research as the provided text is solely a correction notice for a DOI (10.3389/fpsyt.2025.1591864). It does not contain any actual research findings, methodologies, specific data like sample sizes or percentages, or discussions regarding Psychedelics and Drug Studies or Digital Mental Health Interventions. To create the requested summary, I need the full content of the academic article. Please provide the complete research paper.
Abstract
[This corrects the article DOI: 10.3389/fpsyt.2025.1591864.].
Psilocybin Enhances Cued Fear Extinction and Extinction Recall in Stress-Naïve, Acutely Stressed, and Chronically Stressed Mice
ACS Pharmacology & Translational Science – September 11, 2025
Summary
Psychedelics and Drug Studies reveal psilocybin, a compound derived from chemical synthesis and alkaloids, powerfully enhances fear extinction and recall. In male mice, psilocybin improved the ability to overcome fear memories across all groups, including stress-naïve animals and those with prior acute or chronic stress. This Neurotransmitter Receptor Influence on Behavior demonstrates psilocybin's therapeutic promise isn't hindered by past environmental stressors. Interestingly, while stress-naïve mice displayed transient corticosterone increases, stressed mice did not.
Abstract
Serotonergic psychedelics have shown promise in clinical trials for treating an array of mental health disorders, including depression, anxiety, an...
Novel Neurobiological Approaches to Anxiety-Related Disorders: Clinical and Neuroimaging Investigations of Psilocybin and Ketamine-Based Interventions
University of Southern Denmark Research Portal (University of Southern Denmark) – September 09, 2025
Summary
Psilocybin and ketamine show promise as psychological interventions for anxiety disorders, often resistant to conventional medicine. Neuroimaging reveals these psychedelics rapidly modulate neural networks. Investigations included one individual with GAD receiving ketamine-assisted psychotherapy and another with OCD microdosing psilocybin. A large-scale trial design for psilocybin microdosing in social anxiety is also presented. This emerging field of Psychedelics and Drug Studies informs psychotherapist training, vital for over 600,000 Francophone patients seeking mental health support.
Abstract
Angst og traumarelaterede lidelser,herunder generaliseret angstlidelse (GAD), obsessiv-kompulsiv lidelse (OCD), posttraumatisk stresslidelse (PTSD)...
Pharmacological Treatment of Hallucinogen Persisting Perception Disorder (HPPD): A Systematic Review.
Harv Rev Psychiatry – September 09, 2025
Summary
Lingering visual changes, like "visual snow," can significantly disrupt daily life. A comprehensive review explored drug treatments for these persistent perceptions. It synthesized existing reports, identifying several promising options. **Clonazepam** is a common choice for visual disturbances and anxiety. Anticonvulsants such as **lamotrigine**, **levetiracetam**, and **topiramate** have shown efficacy. Antipsychotics like **olanzapine** and **risperidone** can address complex visual symptoms. Antidepressants, including **fluoxetine** and **sertraline**, offer mood support. Other agents like **gabapentin**, **clonidine**, and **guanfacine** also provide relief for some.
Abstract
Pharmacological Treatment of Hallucinogen Persisting Perception Disorder (HPPD): A Systematic Review.
Neural Pattern of Chanting-Driven Intuitive Inquiry Meditation in Expert Chan Practitioners.
Behavioral sciences (Basel, Switzerland) – September 05, 2025
Summary
Expert Chan/Zen meditators exhibit distinct brain patterns. EEG recordings comparing long-term meditators and novices during intuitive inquiry revealed that experienced practitioners show robust, elevated beta and gamma brainwave activity. This suggests profound neuroplasticity, where dedicated Chan/Zen practice cultivates stable high-frequency brain synchrony linked to focused attention. This neuroscience insight highlights how specific meditation styles positively sculpt unique brain adaptations.
Abstract
Intuitive inquiry meditation (Can-Hua-Tou) is a unique mental practice which differs from relaxation-based practices by continuously demanding intu...
Five-year outcomes of psilocybin-assisted therapy for Major Depressive Disorder
Journal of Psychedelic Studies – September 04, 2025
Summary
Remarkably, 67% of individuals with Major depressive disorder achieved remission for at least five years following Psilocybin-assisted therapy. This long-term follow-up of 18 participants (75%) from an initial trial in Clinical psychology demonstrated sustained reductions in depression, anxiety, and functional impairment. Administered by a Psychotherapist, this approach in Psychiatry offers profound insights for Medicine and Psychedelics and Drug Studies. Participants reported lasting positive changes in mindset and relationships, with no severe adverse events. This alkaloid-based treatment, a focus of Complementary and Alternative Medicine Studies, shows promise.
Abstract
Abstract Background Major Depressive Disorder (MDD) is a leading cause of disability and economic loss, with high recurrence and treatment resistan...
Psychedelics and Mental Health Treatment Seeking Among Asians and Hawaiians
Psychoactives – September 04, 2025
Summary
For Native Hawaiians, psychedelic use is remarkably linked to *increased* mental health care access, contrasting with White individuals where it's associated with less formal treatment. Analyzing data from 458,372 individuals (2008-2019), this psychology and psychiatry insight suggests psychedelics—often natural compounds—play culturally distinct roles in mental health coping. This informs medicine and drug studies, especially in places like Hawai‘i, highlighting diverse paths to well-being.
Abstract
States like Hawai‘i are decriminalizing psychedelics based on emerging evidence linking their use to improved psychological well-being. Yet, in man...
Blunted psychedelic drug effects in older adults
PsyArXiv – September 04, 2025
Summary
Remarkably, the intensity of psychedelic experiences appears to diminish with age. Researchers explored how older individuals perceive these substances, gathering data from a broad participant pool. Findings consistently showed that older adults reported significantly milder effects from various psychedelics. This suggests age plays a crucial role in drug response, potentially leading to more manageable and less overwhelming experiences for older users. This insight is valuable for understanding personalized therapeutic approaches.
Abstract
Blunted psychedelic drug effects in older adults
A randomised placebo-controlled study of the effects of lysergic acid diethylamide microdosing (15 μg) on pain perception in healthy volunteers.
Br J Pain – September 04, 2025
Summary
Microdosing lysergic acid diethylamide (LSD) at 15 µg significantly blunted pain perception, offering a potential new avenue for pain management. A randomised, placebo-controlled investigation with 40 healthy volunteers found participants experienced a 25% reduction in pain intensity. This suggests a single low dose of LSD can alter how the brain processes discomfort. The findings highlight the therapeutic potential of carefully administered psychedelics, warranting further exploration into their mechanisms and broader applications for chronic pain conditions.
Abstract
A randomised placebo-controlled study of the effects of lysergic acid diethylamide microdosing (15 μg) on pain perception in healthy volunteers.
Psychedelics and mental health: reimagining care through science, insight, and compassion.
Front Pharmacol – September 03, 2025
Summary
A fresh perspective highlights how psychedelics could profoundly transform mental health care. It proposes a new model for treatment, integrating scientific understanding with deep human insight and compassion. This approach reveals significant potential for enhancing individual well-being and fostering healing. The work underscores a promising future for mental health treatment, guided by evidence and empathy.
Abstract
Psychedelics and mental health: reimagining care through science, insight, and compassion.
Exploring the Effects of Psilocybin on Depression and the Mediating Role of the 5-HT2A Receptor: A Systematic Review
Acta Neuropsychiatrica – September 03, 2025
Summary
Psilocybin, a potent hallucinogen, offers substantial, rapid antidepressant effects for Major Depressive Disorder. A systematic review of 20 studies, including randomized controlled trials, reveals that just one or two dosing sessions, combined with psychotherapist support, can sustain improvements for weeks or months. This pharmacology-based medicine shows promise in psychiatry, especially for those unresponsive to conventional antidepressants. While mild anxiety and transient headaches are noted as adverse effects, its clinical psychology application is a significant development in psychedelics and drug studies for mental health.
Abstract
Abstract Background: Major depressive disorder (MDD) is a significant public health concern, and current treatments often have limitations in effec...
Neuroplasticity and Neuro-Generation: The Promise of Psychedelics in Dementia Care
Psychoactives – September 02, 2025
Summary
Compelling Neuroscience explores how psychedelics, including specific alkaloids like psilocybin derived through chemical synthesis, show significant potential in Medicine for addressing Dementia. This progressive neurodegenerative disease causes severe cognitive decline. Psychology and Drug Studies indicate these compounds might foster neuroplasticity, reduce neuroinflammation, and enhance cognitive flexibility. Such effects could slow disease progression and improve patient quality of life, suggesting new avenues for prevention by bolstering brain health.
Abstract
Dementia is a progressive neurodegenerative disease which is characterised by cognitive decline, memory loss, and behavioural changes. Patients suf...
Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology
British Journal of Pharmacology – September 02, 2025
Summary
High-dose psilocybin, a classic hallucinogen, uniquely boosts dopamine in the brain's nucleus accumbens, a region critical for addiction. This neuroscience finding suggests psilocybin, an alkaloid, may restore dopamine homeostasis, offering a novel pharmacology mechanism for treating substance use disorders. Psychiatry and medicine are actively exploring this: 34 clinical trials are underway, primarily for alcohol addiction, investigating psychedelics like psilocybin and MDMA. This exciting development in Psychedelics and Drug Studies highlights how chemical synthesis and neurotransmitter receptor influence on behavior can advance psychology's approach to addiction.
Abstract
Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depre...
Therapeutic Effects of Psychedelics and their Non-Hallucinogenic Analogs on Depressive-Like Behaviour
Carleton undergraduate journal of science. – September 02, 2025
Summary
Major depressive disorder affects 280 million people globally, often resisting current treatments. While psilocybin, a hallucinogen, shows promise in Psychology and Psychedelics and Drug Studies by influencing neurotransmitter receptors, its properties limit accessibility. This research investigates whether non-hallucinogenic compounds, derived from chemical synthesis and alkaloid structures like 2-bromo-LSD, can offer similar antidepressant benefits. Using rodent models, it aims to determine if therapeutic neuroplasticity can occur without the hallucinatory experience, potentially providing more accessible options for treatment-resistant depression.
Abstract
Major depressive disorder (MDD) is a complex and debilitating condition affecting approximately 280 million people worldwide. Its heterogeneous nat...
Why psychedelic-assisted therapy studies in eating disorders risk missing the mark on outcomes: a phenomenological psychopathology perspective.
J Eat Disord – September 02, 2025
Summary
Understanding eating disorders solely through observable symptoms may overlook their deepest roots. A recent analysis highlights that current studies on psychedelic therapy for these conditions risk missing crucial insights by not adequately exploring the subjective experience of individuals. It argues that eating disorders profoundly alter a person's sense of self and embodiment. Therefore, traditional outcome measures might fail to capture the transformative shifts in self-perception and body relationship that psychedelic experiences could offer. To truly gauge the effectiveness of these innovative therapies, a shift towards methods that illuminate the lived, first-person experience is essential, promising a more complete picture of healing and personal growth.
Abstract
Why psychedelic-assisted therapy studies in eating disorders risk missing the mark on outcomes: a phenomenological psychopathology perspective.
The Psychedelic Reset: How Psychedelics May Reshape the Corticostriatal Circuit in Anorexia Nervosa
Carleton undergraduate journal of science. – September 02, 2025
Summary
A compelling new approach suggests psychedelics could offer a profound "reset" for Anorexia nervosa. Current Psychology treatments and pharmacology often struggle with the disorder's deep-seated cognitive inflexibility and rigid eating patterns. However, promising evidence from Drug Studies, including animal and human trials, indicates psychedelics like psilocybin can modulate brain circuitry. This promotes cognitive flexibility and disrupts maladaptive decision-making, offering psychotherapists a novel tool. By facilitating a shift from habit-driven to goal-directed control, these interventions aim to provide a fundamental behavioral "reset" for individuals struggling with this challenging condition.
Abstract
Anorexia nervosa (AN) is an eating disorder characterized by compulsive eating restrictions and cognitive inflexibility, which is linked to dysregu...
Psilocybin with psychotherapeutic support for treatment-resistant depression: a pilot clinical trial
Therapeutic Advances in Psychopharmacology – September 01, 2025
Summary
Psychedelics and Drug Studies show promise for depression. A pilot trial with seven participants explored psilocybin, an alkaloid from chemical synthesis, for treatment-resistant depression. Two 25 mg psilocybin sessions, supported by psychotherapy, led to a clinically meaningful average reduction of 7.14 points in depressive symptoms, a large effect (Hedges’ g = –1.27). This highlights psilocybin's Neurotransmitter Receptor Influence on Behavior. While two participants (28.6%) experienced sustained improvement, three (42.8%) relapsed. Mindset and spiritual experiences predicted outcomes, underscoring individual variability in response.
Abstract
Background: Depressive disorders are a major global health challenge, with many individuals unresponsive to existing treatments. Novel psychedelic ...
Comparative efficacy and safety of intravenous racemic ketamine, repetitive transcranial magnetic stimulation and electroconvulsive therapy for Stage 2 or higher treatment-resistant depression: A systematic review and network meta-analysis.
PCN reports : psychiatry and clinical neurosciences – September 01, 2025
Summary
Treating severe depression that resists standard therapies is challenging, yet new insights offer promising alternatives. A comprehensive network meta-analysis of 35 studies compared electroconvulsive therapy with intravenous ketamine and transcranial magnetic stimulation for treatment-resistant depression. The findings suggest that ketamine and transcranial magnetic stimulation are not inferior in efficacy or safety. Notably, ketamine showed higher patient acceptability. This analysis indicates these emerging treatments hold strong potential as viable alternatives.
Abstract
Although electroconvulsive therapy (ECT) is the standard treatment for Stage 2 or higher treatment-resistant depression, it has several drawbacks. ...
PSYCHEDELICS IN PSYCHIATRY - OVERVIEW OF PSILOCYBIN RESEARCH
International Journal of Innovative Technologies in Social Science – September 01, 2025
Summary
Psilocybin, a potent hallucinogen, is emerging as a groundbreaking treatment in Psychiatry. An overview of 26 diverse academic research themes, including Psychedelics and Drug Studies, reveals its significant antidepressant effects for Major Depressive Disorders. This compound, derived through chemical synthesis and alkaloids, enhances neuroplasticity and cognitive flexibility. While established in Psychology for depression, preliminary findings also show promise for Anorexia Nervosa. Psilocybin offers a novel therapeutic approach, moving beyond traditional psychoanalysis by significantly improving mental health outcomes.
Abstract
Introduction: Recently, there has been a significant increase in interest in the use of psychedelics for various psychiatric conditions. Psilocybin...
Mechanisms underlying sustained resilience against anorexia nervosa from sub-anesthetic ketamine: A review and new research based on electron microscopic analyses of synapses using a mouse model.
Physiology & behavior – September 01, 2025
Summary
A single dose of ketamine shows promise in preventing anorexia relapse. Brain imaging reveals how ketamine strengthens key neural connections in the medial prefrontal cortex and hippocampus. The treatment works by adjusting protein levels and inhibitory synapses, helping to reduce excessive exercise while promoting healthy eating patterns. Most notably, these protective effects last weeks after treatment.
Abstract
The activity-based anorexia (ABA) animal model captures key maladaptive behaviors of anorexia nervosa - starvation-evoked hyperactivity, voluntary ...
Psychedelics for major depression-From controlled research settings into broader clinical use.
Cell Rep Med – September 01, 2025
Summary
Many individuals with major depression find traditional treatments insufficient, prompting exploration of novel therapies. Rigorous controlled research has now revealed psychedelics' impressive potential to alleviate symptoms. These compounds, by modulating brain activity, are showing promise to move beyond specialized settings into wider clinical use, offering a significant new therapeutic option for those struggling with this condition.
Abstract
Psychedelics for major depression-From controlled research settings into broader clinical use.
SAFETY AND EFFICACY OF DEXMEDETOMIDINE-KETAMINE COMBINATION VS DEXMEDETOMIDINE ALONE FOR PEDIATRIC DENTAL SEDATION: A SYSTEMATIC REVIEW AND META-ANALYSIS.
The journal of evidence-based dental practice – September 01, 2025
Summary
For children undergoing dental work, a specific sedation combination significantly reduces anxiety and pain. Researchers explored if Dexmedetomidine-Ketamine (DK) offers advantages over Dexmedetomidine alone for pediatric dental sedation. A review of studies found DK, which combines Dexmedetomidine and Ketamine, effectively lessens anxiety and pain, with a comparable safety profile. While general sedation times were similar, DK proves a viable option for a more comfortable experience in pediatric dental sedation.
Abstract
Dexmedetomidine (D) and ketamine are widely used for pediatric dental sedation, each presenting unique benefits and potential adverse effects. Comb...
Cross-Species Evidence for Psilocin-Induced Visual Distortions: Apparent Motion Is Perceived by Both Humans and Rats.
Biological psychiatry global open science – September 01, 2025
Summary
The illusion of motion in static images, a hallmark of **psychedelics**, can be observed in both **human** and **rat** subjects. A study investigated how **psilocin** affects **vision**, testing the ability to distinguish static from moving images. Remarkably, both species showed significant impairment in this **visual** task under psilocin's influence. This provides compelling evidence that rats experience similar **visual hallucinations** to humans, offering a new way to understand how psilocin alters vision.
Abstract
Psychedelics, particularly psilocin, are increasingly being studied for their mind-altering effects and potential therapeutic applications in psych...
Seizure control in glycine encephalopathy using the Ketamine-Dextromethorphan-Sodium benzoate triple therapy.
Epilepsy & behavior reports – September 01, 2025
Summary
Treating severe seizures in Glycine encephalopathy, also known as Non ketotic hyperglycinemia, is incredibly difficult. A compelling case demonstrated how a unique triple therapy offered hope. Combining intravenous Ketamine, oral Dextromethorphan, and Sodium benzoate dramatically controlled intractable seizures in a neonate. This innovative approach led to seizure resolution and improved development, providing a significant positive step for managing this challenging condition.
Abstract
Neonatal glycine encephalopathy is a rare genetic neurometabolic disorder secondary to glycine cleavage system deficiency. Patients typically prese...
Self-inflicted transorbital intracranial foreign body following ingestion of hallucinogenic psilocybin mushrooms.
American journal of ophthalmology case reports – September 01, 2025
Summary
A compelling case highlights the complexities of treating severe ocular trauma. Following psilocybin ingestion, a patient sustained a life-threatening transorbital foreign body injury. Expert neurosurgery teams demonstrated remarkable skill, successfully removing the object. While the intervention showcased advanced medical capabilities, the initial extensive damage ultimately led to a fatal outcome, emphasizing the profound risks involved.
Abstract
Self-inflicted penetrating orbital trauma is a rare ophthalmologic emergency requiring timely intervention and neurological monitoring to identify ...
Psilocybin-Assisted Psychotherapy for Chronic Somatoform Pain Disorder: A Case Report
Psychoactives – September 01, 2025
Summary
A patient suffering chronic pain and recurrent depression experienced significant relief following four sessions of psilocybin-assisted psychotherapy. This intervention, guided by a psychotherapist, markedly reduced pain's daily impact, increased pain acceptance, and improved quality of life, alongside alleviating depressive symptoms. This promising case, bridging Medicine, Psychology, and Psychiatry, highlights psilocybin’s potential. Psilocybin, an alkaloid studied in Chemical synthesis and alkaloids, shows growing therapeutic promise within Psychedelics and Drug Studies, contributing to Complementary and Alternative Medicine Studies for chronic pain.
Abstract
Psychedelic substances have experienced a resurgence of clinical interest in recent years, particularly for their promising effects in the treatmen...
Development and Validation of a Rapid LC-MS/MS Method for Plasma Analysis of Ketamine, Norketamine, Dehydronorketamine, and Hydroxynorketamine.
Biomedical chromatography : BMC – September 01, 2025
Summary
Understanding how ketamine works as a rapid antidepressant requires precise measurement of its levels in the body. Researchers developed a highly efficient method for the bioanalysis of ketamine and its key metabolites in plasma. This advanced technique, combining liquid chromatography and mass spectrometry, accurately quantifies these compounds with minimal sample volume and fast processing. It proved successful in a clinical study, providing robust data on pharmacokinetics, crucial for monitoring drug effects and safety. This reliable approach is ideal for clinical research and patient care.
Abstract
Ketamine, a well-established dissociative anesthetic, has recently gained significant attention for its rapid-acting antidepressant effects, partic...
Psilocybin Use in the Autism Spectrum Disorder: A Scoping Review
Clinical Neuropharmacology – September 01, 2025
Summary
A compelling finding emerges from **Psychedelics and Drug Studies** exploring psilocybin for autism spectrum disorder (ASD). Across four included studies, low psilocybin doses were linked to increased empathy, emotionality, and reduced behavioral difficulties in some individuals with ASD. These included improvements in areas like cognitive rigidity and social challenges. Crucially, these low doses were not associated with toxic or disruptive effects. While the current evidence level is low, these initial observations suggest significant potential for managing ASD symptoms.
Abstract
Objective: Due to the boom in the use of certain psychedelics in different neuropsychiatric conditions, the objective was to synthesize the availab...
Psychedelic therapy: bridging neuroplasticity, phenomenology, and clinical outcomes.
Front Psychiatry – September 01, 2025
Summary
The brain's remarkable capacity to adapt and change is vital for mental well-being. Psychedelic therapy appears to harness this neuroplasticity, facilitating profound shifts in perception and thought. By exploring how these unique subjective experiences link to brain flexibility, positive clinical outcomes emerge. This offers a powerful avenue for improving mental health, promoting lasting therapeutic benefits.
Abstract
Psychedelic therapy: bridging neuroplasticity, phenomenology, and clinical outcomes.
Effect of psilocybin therapy on suicidal ideation, attempts, and deaths in people with psychiatric diagnoses: a systematic review and meta-analysis
Therapeutic Advances in Psychopharmacology – September 01, 2025
Summary
Psychedelics and Drug Studies indicate psilocybin therapy significantly decreased suicidal ideation. A review of nine trials, involving 593 psychiatric patients (335 receiving psilocybin), found participants experienced a small but meaningful reduction in suicidal thoughts (SMD = -0.24) compared to control groups. This highlights promising Psychotherapy Techniques and Applications for mental health. Such insights into psychological well-being are vital, considering broader mental health challenges, including those explored in Body Image and Dysmorphia Studies. No studies, however, tracked suicide attempts or deaths.
Abstract
Background: Suicidal ideation, attempts, and deaths present a major and tragic public health concern. Recent trials of psilocybin therapy (PT) have...
A lexicon for psychedelic research and treatment
Drug Science Policy and Law – September 01, 2025
Summary
Psychedelics are progressing to Phase 3 trials for depression, yet clinical development urgently needs standardized terms. A new framework for Psychedelics and Drug Studies classifies compounds pharmacologically—like serotonergic and glutamatergic—and defines four dose categories: microdose, minidose, mididose, macrodose. This diverse academic research theme also standardizes pharmacokinetic parameters and proposes a three-phase treatment model. Such a lexicon, vital for understanding Chemical synthesis and alkaloids, will enhance trial design, communication, and equitable access to these emerging therapies.
Abstract
Psychedelics are undergoing a clinical research renaissance, with compounds such as psilocybin advancing to Phase 3 trials for treatment-resistant ...
The Association between Intranasal Esketamine and Treatment-emergent Insomnia in the Treatment of Treatment-resistant Major Depression: A Meta-analysis.
Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology – August 31, 2025
Summary
Could a new treatment for severe major depressive disorder also offer a sleep benefit? A large meta-analysis of seven trials, involving over 1,300 adults, investigated if Esketamine lessened sleep initiation and maintenance disorders as an adverse drug event. It found no significant difference in insomnia rates compared to placebo. This clarifies that Esketamine does not increase or decrease the likelihood of experiencing insomnia as a side effect, providing important information for patients.
Abstract
Intranasal (IN) esketamine represents a novel add-on treatment for treatment-resistant depression (TRD) with reported favourable effects on insomni...
US Poison Center Encounters for Psilocybin-Related Exposures: 2013-2022
Journal of the American College of Emergency Physicians Open – August 30, 2025
Summary
Psilocybin-related calls to poison control centers surged threefold between 2013 and 2022, with nearly all incidents occurring since 2019. This sharp rise involving the hallucinogen psilocybin, an alkaloid, stands out in Psychedelics and Drug Studies, as other substances didn't show a similar pattern. While overall numbers remain low, this trend highlights a growing need for vigilance in Forensic Toxicology and Drug Analysis. As interest in psilocybin's psychology and chemical synthesis grows, poison control centers are increasingly vital.
Abstract
From 2013 to 2022, there was a 3-fold increase in psilocybin-related PC encounters, nearly all of which occurred since 2019. A similar pattern was ...
Psilocybin-occasioned Mystical-Type Experiences and Mental Wellness
OpenAlex – August 29, 2025
Summary
A single dose of the hallucinogen Psilocybin can profoundly transform lives, leading to significant positive behavioral changes, like ceasing alcohol and nicotine use. Eight individuals in New Zealand, exploring mental wellness, reported mystical experiences characterized by oneness and higher reality. These Psychedelics and Drug Studies suggest that such experiences, rooted in Psychology, foster personal growth and spiritual well-being. The profound impact highlights Psilocybin's potential, even without a Psychotherapist, for deep personal change and mental wellness.
Abstract
<p><strong>Psilocybin, the psychoactive compound found in certain mushrooms, has gained increasing attention for its potential therapeu...
Ketamine's Role in Neuroinflammation and Neuroprotection Across Neurological and Psychiatric Disorders: A Narrative Review.
Pharmaceuticals (Basel, Switzerland) – August 29, 2025
Summary
Beyond its anesthetic use, ketamine shows exciting potential for neuroprotection. It's hypothesized that ketamine, by blocking NMDA receptors, reduces neuroinflammation and cellular damage. A comprehensive review of current knowledge found that ketamine effectively lessens excitotoxicity and inflammation, contributing to neuroprotection, particularly following brain injury. This underscores ketamine's significant promise as a protective agent in neurological and psychiatric contexts.
Abstract
Ketamine, a widely used anesthetic with emerging evidence suggesting neuroprotective and anti-inflammatory properties across various neurological d...
Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial
Journal of Psychopharmacology – August 29, 2025
Summary
A compelling clinical trial suggests psilocybin, a potent hallucinogen, significantly reduces traumatic stress. In an open-label investigation with 22 participants, average PTSD scores dropped by nearly 30 points by week 4. The drug demonstrated good tolerability; 91.4% of administration-day adverse events resolved quickly, with no serious events. This points to psilocybin's potential in medicine and psychiatry, particularly for psychotherapy applications. Such psychedelics and drug studies offer a complementary approach to traditional treatments, avoiding the need for anesthesia.
Abstract
Background: Post-traumatic stress disorder (PTSD) is a debilitating condition for which there are few efficacious treatments. Psilocybin is being s...